Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

History and regulatory issues of generic drugs.

Meyer GF.

Transplant Proc. 1999 May;31(3A Suppl):10S-12S.

PMID:
10330951
2.

Generic substitution: issues for problematic drugs.

Henderson JD, Esham RH.

South Med J. 2001 Jan;94(1):16-21. Review. Erratum in: South Med J. 2001 Dec;94(12):1235.

PMID:
11213935
3.

United States Food and Drug Administration requirements for approval of generic drug products.

Meyer MC.

J Clin Psychiatry. 2001;62 Suppl 5:4-9; discussion 23-4. Review.

PMID:
11305846
4.

Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.

Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J.

Semin Thromb Hemost. 2008 Feb;34(1):74-85. doi: 10.1055/s-2008-1066026. Review.

PMID:
18393144
5.

Issues in the use of generic antiarrhythmic drugs.

Reiffel JA.

Curr Opin Cardiol. 2001 Jan;16(1):23-9. Review.

PMID:
11124715
6.

Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.

Heller WM.

Am J Hosp Pharm. 1993 Feb;50(2):318-22. Review. No abstract available.

PMID:
8480792
7.

The effectiveness of generic agents in psychopharmacologic treatment.

Kumet R, Gelenberg AJ.

Essent Psychopharmacol. 2005;6(2):104-11. Review.

PMID:
15765794
8.

Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.

Davit BM, Chen ML, Conner DP, Haidar SH, Kim S, Lee CH, Lionberger RA, Makhlouf FT, Nwakama PE, Patel DT, Schuirmann DJ, Yu LX.

AAPS J. 2012 Dec;14(4):915-24. doi: 10.1208/s12248-012-9406-x. Review.

PMID:
22972221
9.

Understanding the scientific issues embedded in the generic drug approval process.

Welage LS, Kirking DM, Ascione FJ, Gaither CA.

J Am Pharm Assoc (Wash). 2001 Nov-Dec;41(6):856-67. Review.

PMID:
11765111
10.

Generic and alternative brand-name pharmaceutical equivalents: select with caution.

Hendeles L, Hochhaus G, Kazerounian S.

Am J Hosp Pharm. 1993 Feb;50(2):323-9. Review. No abstract available. Erratum in: Am J Hosp Pharm 1993 May;50(5):913.

PMID:
8480793
11.

A review of the safety of generic drugs.

Dighe SV.

Transplant Proc. 1999 May;31(3A Suppl):23S-24S. Review.

PMID:
10330955
12.

Generic drugs--safe, effective, and affordable.

Peters JR, Hixon DR, Conner DP, Davit BM, Catterson DM, Parise CM.

Dermatol Ther. 2009 May-Jun;22(3):229-40. doi: 10.1111/j.1529-8019.2009.01236.x. Review.

PMID:
19453347
13.

Generic low-molecular-weight heparins: some practical considerations.

Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.

Semin Thromb Hemost. 2004 Dec;30(6):703-13. Review.

PMID:
15630677
14.

Therapeutic equivalents in clinical practice.

Benson MD.

Int J Fertil Womens Med. 2001 Mar-Apr;46(2):89-94. Review.

PMID:
11374660
15.

Brand and generic medications: are they interchangeable?

Al-Jazairi AS, Bhareth S, Eqtefan IS, Al-Suwayeh SA.

Ann Saudi Med. 2008 Jan-Feb;28(1):33-41. Review.

PMID:
18299655
16.

Bioequivalence of racemic drugs.

Nerurkar SG, Dighe SV, Williams RL.

J Clin Pharmacol. 1992 Oct;32(10):935-43. Review.

PMID:
1447402
17.

The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.

Borgheini G.

Clin Ther. 2003 Jun;25(6):1578-92. Review.

PMID:
12860486
18.

Generic drugs: an overview.

Helgeland D.

S D Med. 2006 Apr;59(4):161-3. Review. No abstract available.

PMID:
16681165
19.

Basic facts about biosimilars.

Nowicki M.

Kidney Blood Press Res. 2007;30(5):267-72. Review.

PMID:
17622764
20.

FDA critical path initiatives: opportunities for generic drug development.

Lionberger RA.

AAPS J. 2008;10(1):103-9. doi: 10.1208/s12248-008-9010-2. Review.

PMID:
18446510
Items per page

Supplemental Content

Support Center